TIMKEN WILLIAM R 4
4 · REGEN BIOLOGICS INC · Filed Jan 21, 2009
Insider Transaction Report
Form 4
TIMKEN WILLIAM R
Director
Transactions
- Purchase
Common Stock
2009-01-16$3.50/sh+17,143$60,001→ 59,645 total(indirect: By Trust) - Conversion
Convertible Notes
2009-01-16$10000.00/sh→ 0 total(indirect: By Trust)Exercise: $3.00From: 2008-12-04Exp: 2009-07-24→ Common Stock (3,366 underlying) - Conversion
Common Stock
2009-01-16$3.00/sh+20,689$62,067→ 80,343 total(indirect: By Trust) - Conversion
Convertible Notes
2009-01-16$50000.00/sh→ 0 total(indirect: By Trust)Exercise: $3.00From: 2008-07-24Exp: 2009-07-24→ Common Stock (17,323 underlying) - Purchase
Warrants
2009-01-16+2,572→ 2,572 total(indirect: By Trust)Exercise: $1.20From: 2009-01-16Exp: 2014-01-16→ Common Stock (2,572 underlying)
Footnotes (5)
- [F1]Represents the number of shares issued upon conversion of the convertible notes at $3.00 per share and such conversion amount included the principal amount and any accrued and unpaid interest on the notes. Some convertible notes were originally convertible at $0.15 per share, but the conversion price increased to $3.00 per share after the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F2]Represents the principal amount of the convertible notes purchased and does not include any accrued and unpaid interest on the notes.
- [F3]Represents the number of shares of common stock into which the notes are convertible and such conversion amount includes the principal amount and any accrued and unpaid interest on the notes.
- [F4]Such conversion price was increased from $0.15 to $3.00 per share following the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
- [F5]The warrants were issued pursuant to a Subscription Agreement, dated January 16, 2009, by and between ReGen Biologics, Inc. (the "Company") and each of the investors named therein. Each investor acquired common stock of the Company at $3.50 per share and without additional consideration, the Company provided 15% warrant coverage to each investor exercisable for additional shares of common stock.